

MAGLUMI Osteocalcin (CLIA)



130211003M



100



**Shenzhen New Industries
Biomedical Engineering Co., Ltd**
4F, Wearnes Tech Bldg,
Science & Industry Park,
Nanshan, Shenzhen, 518057 CHINA
Tel. + 86-755-86028224
Fax. + 86-755-26654850



Lotus Global Co., Ltd
15 Alexandra Road
London
NW8 0DP
UK
Tel. + 44-20-75868010
Fax. + 44-20-79006187



FOR PROFESSIONAL USE ONLY

Store at 2-8°C



COMPLETELY READ THE INSTRUCTIONS BEFORE
PROCEEDING



SYMBOLS EXPLANATIONS



Authorized Representative in Europe



Manufacturer



Attention. See Instructions For Use



Contents of kit



In vitro diagnostic medical device
(In vitro diagnostic use)




Lot number



Catalogue Code



Expiry date (Use by...)



Temperature limitation
(store at 2-8°C)



Number of tests



Keep away from sunlight



Keep upright

INTENDED USE

The kit has been designed for the quantitative determination of Osteocalcin (BGP) in human serum.

The method can be used for samples over the range of 0-300ng/ml.

The test has to be performed on the MAGLUMI chemiluminescence immunoassay (CLIA) fully auto analyzer (Including MAGLUMI 1000, MAGLUMI 2000, MAGLUMI 2000 Plus and new developed models).

SUMMARY AND EXPLANATION OF THE TEST

BoneG-Gla Protein, (BGP) is one kind of acidic protein, includes three γ carboxyl group glutamic acid side chain, and its biology characteristic is extremely important, after adding COOH⁻, BGP can hang together with the Ca²⁺. BGP is one of the richest non-ossein proteins in the bone, and it exists generally in skeleton and the dentine of all vertebrate, in the human bones it approximately compose total quantity of the ossein protein 25%. Half-life of BGP in the blood is 4~5min, is a reflection of osteoblast activeness. It has vital significance to the clinical research bone disease and the endocrine metabolic osteopathy pathogenesis, ossein ingredient research.

PRINCIPLE OF THE TEST

Sandwich immunoluminometric assay:

Use an anti-BGP monoclonal antibody to label ABEI, and use another monoclonal antibody to label FITC. Sample, Calibrator or Control with FITC Label and magnetic microbeads coated with anti-FITC are mixed thoroughly and incubated at 37°C, forming antibody-antigen complexes; After sediment in a magnetic field, decant the supernatant and cycle washing for 1 time; then add ABEI Label, incubating and washing for the 2nd time. Subsequently, the starter reagents are added and a flash chemiluminescent reaction is initiated. The light signal is measured by a photomultiplier as RLU within 3 seconds and is proportional to the concentration of BGP present in controls or samples.



KIT COMPONENTS

Material Supplies

| Reagent Integral for 100 determinations | |
|--|--------|
| Nano magnetic microbeads: TRIS buffer, 1.2 % (W/V), 0.2%NaN ₃ , coated with sheep anti-FITC polyclonal antibody. | 2.5ml |
| Calibrator low: bovine serum, 0.2%NaN ₃ . | 3.0ml |
| Calibrator high: bovine serum, 0.2%NaN ₃ . | 3.0ml |
| FITC label: anti-BGP monoclonal antibody labeled FITC contains BSA, 0.2%NaN ₃ . | 12.5ml |
| ABEI label: anti-BGP monoclonal antibody labeled ABEI contains BSA, 0.2%NaN ₃ . | 12.5ml |
| All reagents are provided ready-to-use. | |

| Reagent Vials in kit box | |
|--|-------|
| Internal Quality Control: containing BSA, 0.2%NaN ₃ . (target value refer to Quality Control Information date sheet) | 2.0ml |

Accessories Required But Not Provided

| | |
|--------------------------|-----------------|
| MAGLUMI Reaction Module | REF: 630003 |
| MAGLUMI Starter 1+2 | REF: 130299004M |
| MAGLUMI Wash Concentrate | REF: 130299005M |
| MAGLUMI Light Check | REF: 130299006M |



Preparation of the Reagent Integral

Before the sealing is removed, gentle and careful horizontal shaking of the Reagent Integral is essential (avoid foam formation!) Remove the sealing and turn the small wheel of the magnetic microbeads compartment to and fro, until the colour of the suspension has changed into brown. Place the Integral into the reagent area and let it stand there for 30 min. During this time, the magnetic microbeads are automatically agitated and completely resuspended.

Do not interchange integral component from different reagents or lots!

Storage and Stability

- Sealed: Stored at 2-8 °C until the expiry date.
- Opened: Stable for 4 weeks. To ensure the best kit performance, it is recommended to place opened kits in the refrigerator if it's not going to be used on board during the next 12 hours.



- Keep upright for storage.



- Keep away from direct sunlight.

CALIBRATION AND TRACEABILITY

1) Traceability

To perform an accurate calibration, we have provided the test calibrators standardized against the SNIBE internal reference substance.

Calibrators in the reagent kit are from Sigma.

2) 2-Point Recalibration

Via the measurement of calibrators, the predefined master curve is adjusted (recalibrated) to a new, instrument-specific measurement level with each calibration.

3) Frequency of Recalibration

- After each exchange of lot (Reagent Integral or Starter Reagents).
- Every week and/or each time a new Integral is used (recommendation).
- After each servicing of the MAGLUMI Fully Auto analyzer.
- If controls are beyond the expected range.

SPECIMEN COLLECTION AND PREPARATION

Sample material: serum

Collect samples using standard procedures.

Store at 2-8

below -20 °C

Avoid repeated freezing and thawing cycles, stored samples should be thoroughly mixed prior to use (Vortex mixer).

Please ask local representative of SNIBE for more details if you have any doubt.

Vacuum Tubes

- Blank tubes are recommended type for collecting samples.
- Please ask SNIBE for advice if special additive must be used in sample collecting.

Specimen Conditions

- Do not use specimens with the following conditions:
 - heat-inactivated specimens;
 - Cadaver specimens or body fluids other than human serum;
 - Obvious microbial contamination.

088120410-v1.0-EN

- Use caution when handling patient specimens to prevent cross contamination. Use of disposable pipettes or pipette tips is recommended.
- Inspect all samples for bubbles. Remove bubbles with an applicator stick prior to analysis. Use a new applicator stick for each sample to prevent cross contamination.
- Serum specimens should be free of fibrin, red blood cells or other particulate matter.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the specimen is centrifuged before a complete clot forms, the presence of fibrin may cause erroneous results.

Preparation for Analysis

- Patient specimens with a cloudy or turbid appearance must be centrifuged prior to testing. Following centrifugation, avoid the lipid layer (if present) when pipetting the specimen into a sample cup or secondary tube.
- Specimens must be mixed **thoroughly** after thawing by **low** speed vortexing or by gently inverting, and centrifuged prior to use to remove red blood cells or particulate matter to ensure consistency in the results. Multiple freeze-thaw cycles of specimens should be avoided.
- All samples (patient specimens or controls) should be tested within 3 hours of being placed on board the MAGLUMI System. Refer to the SNIBE service for a more detailed discussion of onboard sample storage constraints.


Storage

- If testing will be delayed for more than 8 hours, remove serum or plasma from the serum or plasma separator, red blood cells or clot. Specimens removed from the separator gel, cells or clot may be stored up to 24 hours at 2-8°C.
- Specimens can be stored up to 30 days frozen at -20°C or colder.

Shipping

- Before shipping specimens, it is recommended that specimens be removed from the serum or plasma separator, red blood cells or clot. When shipped, specimens must be packaged and labeled in compliance with applicable state, federal and international regulations covering the transport of clinical specimens and infectious substances. Specimens must be shipped frozen (dry ice). Do not exceed the storage time limitations identified in this section of the package insert.

WARNING AND PRECAUTIONS FOR USERS



For use in *IN-VITRO* diagnostic procedures only.
°C: 24 hours, for longer storage periods, freeze to

- Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert.

Safety Precautions

CAUTION: This product requires the handling of human specimens.

- The calibrators in this kit are prepared from bovine serum products. However, because no test method can offer complete assurance that HIV, Hepatitis B Virus or other infectious agents are absent; these reagents should be considered a potential biohazard and handled with the same precautions as applied to any serum or plasma specimen.
- All samples, biological reagents and materials used in the assay must be considered potentially able to transmit infectious agents. They should therefore be disposed of in accordance with the prevailing regulations and guidelines of

the agencies holding jurisdiction over the laboratory, and the regulations of each country. Disposable materials must be incinerated; liquid waste must be decontaminated with sodium hypochlorite at a final concentration of 5% for at least half an hour. Any materials to be reused must be autoclaved using an overkill approach (USP 24, 2000, p.2143). A minimum of one hour at 121 °C is usually

considered adequate, though the users must check the effectiveness of their decontamination cycle by initially validating it and routinely using biological indicators.

- It is recommended that all human sourced materials be considered potentially infectious and handled in accordance with the OSHA Standard on Bloodborne Pathogens 13. Biosafety Level 214 or other appropriate biosafety practices should be used for materials that contain or are suspected of containing infectious agents.
- This product contains Sodium Azide; this material and its container must be disposed of in a safe way.
- Safety data sheets are available on request.

Handling Precautions

- Do not use reagent kits beyond the expiration date.
- Do not mix reagents from different reagent kits.
- Prior to loading the Reagent Kit on the system for the first time, the microbeads requires mixing to re-suspend microbeads that have settled during shipment.
- For microbeads mixing instructions, refer to the KIT COMPONENTS, Preparation of the Reagent Integral section of this package insert.
- To avoid contamination, wear clean gloves when operating with a reagent kit and sample.
- Over time, residual liquids may dry on the kit surface, please pay attention the silicon film still exists on the surface of the kit.
- For a detailed discussion of handling precautions during system operation, refer to the SNIBE service information.

TEST PROCEDURE

To ensure proper test performance, strictly adhere to the operating instructions of the MAGLUMI Fully Auto analyzer. Each test parameter is identified via a RFID tag on the Reagent Integral. For further information please refer to the MAGLUMI Chemiluminescence Analyzer Operating Instructions.

| | |
|--------|--------------------------------|
| 80µl | Sample, calibrator or controls |
| +100µl | FITC Label |
| +20µl | Nano magnetic microbeads |
| 10 min | Incubation |
| 400µl | Cycle washing |
| +100µl | ABEI Label |
| 10 min | Incubation |
| 400µl | Cycle washing |
| 3 s | Measurement |

DILUTION

Sample dilution by analyzer is not available in this reagent kit. Samples with concentrations above the measuring range can be diluted manually. After manual dilution, multiply the result by the dilution factor.

Please choose applicable diluents or ask SNIBE for advice before manual dilution must be processed.

QUALITY CONTROL

- Observe quality control guidelines for medical laboratories
- Use suitable controls for in-house quality control. Controls should be run at least once every 24 hours when the test is in use, once per reagent kit and after every calibration. The control intervals should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined ranges. Each laboratory should establish guidelines for corrective measures to be taken if values fall outside the range.

088120410-v1.0-EN

LIMITATIONS OF THE PROCEDURE

1) Limitations

Patients with malignancies may exhibit BGP values within the normal range. BGP concentrations may be elevated in case of liver cirrhosis, hepatitis or tyrosinaemia. Thus, BGP determination is more suitable for therapeutic monitoring and follow-up as well as for a comparison with histological results. BGP serum levels may only be interpreted in context with the clinical picture and other diagnostic procedures. The BGP assay should not be used as the only criterion for cancer screening.

2) Interfering Substances

No interference with test results is seen by concentrations of bilirubin<0.125mg/ml, haemoglobin<16mg/dl or triglycerides<12.5mg/ml.

3) HAMA

Patient samples containing human anti-mouse antibodies (HAMA) may give falsely elevated or decreased values. Although HAMA-neutralizing agents are added, extremely high HAMA serum concentrations may occasionally influence results.

4) High-Dose Hook

No high-dose hook effect was seen for BGP concentrations up to 1000ng/ml.

RESULTS

1) Calculation of Results

The analyzer automatically calculates the BGP concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in ng/ml. For further information please refer to the MAGLUMI Chemiluminescence Analyzer Operating Instructions.

2) Interpretation of Results

- Results of study in clinical centers with group of individuals, 95% of the results were:0.5-5.0ng/ml.
- Results may differ between laboratories due to variations in population and test method. If necessary, each laboratory should establish its own reference range.

PERFORMANCE CHARACTERISTICS

1) Precision

Intra-assay coefficient of variation was evaluated on 3 different levels of control serum repeatedly measured 20 times in the same run, calculating the coefficient of variation.

| Intra-assay precision | | | |
|-----------------------|-------------|-----------|------|
| Control | Mean(ng/ml) | SD(ng/ml) | CV% |
| Level 1 | 0.81 | 0.05 | 5.93 |
| Level 2 | 4.93 | 0.27 | 5.44 |
| Level 3 | 27.33 | 1.56 | 5.72 |

Inter-assay coefficient of variation was evaluated on three batches of kits. Repeatedly measured 3 different levels of control serum 21 times, calculating the coefficient of variation.

| Inter-assay precision | | | |
|-----------------------|-------------|-----------|------|
| Control | Mean(ng/ml) | SD(ng/ml) | CV% |
| Level 1 | 0.76 | 0.07 | 9.86 |
| Level 2 | 5.02 | 0.49 | 9.73 |
| Level 3 | 26.86 | 2.54 | 9.45 |

2) Analytical Sensitivity

The sensitivity is defined as the concentration of BGP equivalent to the mean RLU of 20 replicates of the zero standard plus two standard deviations corresponding to the concentration from the standard curve. The sensitivity is typically less than 0.13ng/ml.

3) Specificity

The specificity of the BGP assay system was assessed by

measuring the apparent response of the assay to various potentially cross reactive analytes.

| Compound | Concentration | Cross reactivity |
|----------|---------------|------------------|
| CT | 20 ng/ml | 0.6% |
| PTH | 5000 pg/ml | 1.0% |

4) Recovery

Consider calibrator high of known concentration as a sample, dilute it by 1:2 ratio with diluents, and measure its diluted concentration for 10 times. Then calculate the recovery of measured concentration and expected concentration. The recovery should be within 90% -110%.

| Expected | Mean Measuring | Recovery |
|-------------|----------------|----------|
| 14.058ng/ml | 13.614ng/ml | 96% |

5) Linearity

Use BGP calibrator to prepare the six-point standard curve, measuring all points' RLU except point A, and then do four-parameter linear fitting in double logarithm coordinate, the absolute linear correlation coefficient(r) should be bigger than 0.9800.

| Calibrator Point | Concentration ng/ml | Absolute linear correlation coefficient (r) |
|------------------|---------------------|---|
| A | 0 | |
| B | 0.5 | r=0.9843 |
| C | 2 | |
| D | 5 | |
| E | 15 | |
| F | 50 | |

6) Method comparison

A comparison of MAGLUMI Osteocalcin (y) with a commercially available Osteocalcin test (x) using clinical samples gave the following correlations (ng/ml):

Linear regression

$$y = 0.97x + 8.0$$

$$r = 0.974$$

$$S_{y.x} = 11.8$$

Number of samples measured: 200

The sample concentrations were between 0.5 and 274 ng/ml.

REFERENCES

1. Y. Z. Bagger, H. B. Rasmussen, P. Alexandersen, T. Werge, C. Christiansen, L. B. Tankó. Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis? [J], 2007.
2. Yih-Jing Tang, Wayne Huey-Herng Sheu, Pi-Haw Liu, Wen-Jane Lee, Ying-Tsung Chen. Positive associations of bone mineral density with body mass index, physical activity, and blood triglyceride level in men over 70 years old: a TCVGHAGE study [J], 2007.
3. P. Gerdhem, A. Isaksson, K. Åkesson, Karl J. Obrant. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus [J], 2005.
4. P. Pennisi, S. S. Signorelli, S. Riccobene, G. Celotta, L. Pino, T. Malfa, C. E. Fiore. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. [J], 2004.
5. S. Adami, V. Braga, M. Zamboni, Davide Gatti, M. Rossini, J. Bakri, E. Battaglia. Relationship Between Lipids and Bone Mass in 2 Cohorts of Healthy Women and Men [J], 2004.
6. Samy I. McFarlane MD, FACP, Ranganath Muniyappa, John J. Shin, Gul Bahtiyar, James R. Sowers. Osteoporosis and cardiovascular disease [J], 2004.

7. M. T. Rosato, S. H. Schneider, S. A. Shapses. Bone Turnover and Insulin-like Growth Factor I Levels Increase After Improved Glycemic Control in Noninsulin-dependent Diabetes Mellitus [J], 1998.

8. Dr. H. Rico, E. R. Hernandez, J. A. Cabranes, F. Gomez-Castresana. Suggestion of a deficient osteoblastic function in diabetes mellitus: The possible cause of osteopenia in diabetics [J], 1989.